Predict your next investment

Oxford Nanopore Technologies company logo
HEALTHCARE | Medical Devices & Equipment
nanoporetech.com

See what CB Insights has to offer

Founded Year

2005

Stage

Series I | Alive

Total Raised

$1.179B

Valuation

$0000 

Last Raised

$270.93M | 4 mos ago

About Oxford Nanopore Technologies

Oxford Nanopore Technologies develops a nanopore DNA sequencer, the MinION. The MinION is a portable, real-time, long-read, low-cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.

Oxford Nanopore Technologies Headquarter Location

Oxford, England, OX4 4DQ,

United Kingdom

+44 (0)845 034 7900

Latest Oxford Nanopore Technologies News

Oxford Nanopore Technologies Registers for IPO on London Stock Exchange

Sep 13, 2021

Save for later NEW YORK – Oxford Nanopore Technologies last week filed a registration document for an initial public offering on the London Stock Exchange. The company had first announced in March its intention to go public on the LSE in the second half of this year. At that time, IP Group, its largest shareholder, said it valued Oxford Nanopore at around £2.27 billion ($3.14 billion). "Our differentiated commercial model and technology platform, where devices range from low-cost plug-and-play sequencing in the palm of your hand to industrial-scale installations, significantly expands the potential customer communities who could benefit from the technology," Gordon Sanghera, Oxford Nanopore's CEO, said in an Expected Intention to Float announcement. "We believe Oxford Nanopore is ideally suited to both disrupt existing markets and create entirely new ones. An IPO will be a step on the journey to make our vision a reality, supporting our ambitious growth plans and enhancing our ability to innovate and grow.” According to the EITF filing, the company plans to sell both new shares and shares from existing shareholders in the offer and intends to float at least 25 percent of its total shares on the LSE. Oxford Nanopore plans to disclose additional details about the IPO in a future Intention to Float announcement and prospectus. The company has hired Merrill Lynch International, Citigroup Global Markets, and JP Morgan Securities (conducting its UK investment banking business as JP Morgan Cazenove) as joint global coordinators and Barclays Bank; Joh. Berenberg, Gossler & Co. London Branch; Guggenheim Securities; Numis Securities; and RBC Europe as joint bookrunners for the offer. The firm said in its EITF filing that it estimates the DNA/RNA sequencing market to be worth $5.7 billion in 2021, with an annual growth rate of 18 percent between 2020 and 2023, based on a report from DeciBio. It also believes its nanopore platform can expand the DNA/RNA sequencing market with applications in healthcare, agriculture, food, and other areas. Oxford Nanopore also reported life science research tools revenues of £52.6 million ($72.8 million) for the first half of 2021, more than double its LSRT revenues in the first half of 2020. Meanwhile, revenues from COVID testing declined 72 percent in H1 of 2021. For full year 2021, management expects total revenue growth to be affected by further declines in COVID testing in the second half of the year, following the global rollout of vaccines. "The Group therefore remains strategically focused on driving growth in its core LSRT business," according to the document. Specifically, the firm expects LSRT revenues to grow 30 to 40 percent in 2021, and LSRT revenues to reach £165 million to £175 million in 2023. Last month , Oxford Nanopore reported a 119 percent increase in 2020 total revenues to £113.9 million, driven by £65.5 million in LSRT revenues and £48.3 million in COVID-19 testing revenue.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Oxford Nanopore Technologies

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Oxford Nanopore Technologies in 1 CB Insights research brief, most recently on Jun 24, 2021.

Expert Collections containing Oxford Nanopore Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Nanopore Technologies is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

U

Unicorns- Billion Dollar Startups

817 items

M

Medical Devices

7,770 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

N

Nanobiotechnology

704 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

H

Health & Wellness Assessment

3,053 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

I

Infectious Disease

2,263 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Oxford Nanopore Technologies Patents

Oxford Nanopore Technologies has filed 162 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/22/2019

9/7/2021

Molecular biology, DNA, Genetics, Biotechnology, RNA

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/22/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, DNA, Genetics, Biotechnology, RNA

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Oxford Nanopore Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford Nanopore Technologies Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.